4[5]Bouza E, Garcia-Garrote F, Cercenado E, et al. Pseudomonas aeruginosa: a survey of resistance in 136 hospital in Spain[J]. Antimicrob Agents Chemother, 1999, 43(4): 981-982.
5[9]Niitsuma K, Saitoh M, Kojimabara M, et al. Antimicrobial suscieptibility of Pseudomonas aeruginosa isolated in Fukushima Prefecture[J]. Jpn J Antibiot, 2001, 54(2): 79-87.
6Lindenfeld J,Page RL 2nd,Zolty R,et al.Drug therapy in the heart transplant recipient:Part Ⅲ:common medical problems.Circulation,2005,111(1):113-117.
7Antretter H,Hofer D,Hangler H,et al.Is it possible to reduce CMV-infections after heart transplantation with a three-month antiviral prophylaxis? 7 years experience with ganciclovir.Wien Klin Wochenschr,2004,116(15-16):542-551.
8McNeil K,Foweraker J,Wreghitt T.Infectious complications of lung transplantation.In:Banner NR,Polak JM,Yacoub MH.Lung Transplantation.Cambridge,UK:Cambridge University Press,2003.250-260.
9Kotloff RM,Ahya VN.Medical complications of lung transplantation.Eur Respir J,2004,23 (2):334-342.
10Wieland T,Liebold A,Jagiello M,et al.Superiority of voriconazole over amphotericin B in the treatment of invasive aspergillosis after heart transplantation.J Heart Lung Transplant,2005,24(1):102-104.
